



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Bae Abertawe
Swansea Bay University
Health Board

Cadeirydd Dros Dro/ Interim Chair: **Emma Woollett**
Prif Weithredwr/Chief Executive: **Tracy Myhill**

gofalu am ein gilydd, cydweithio, gwella bob amser
caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 20th September 2019
Ein Cyf / Our Ref: 19-I-001

☎ 01639 648363
✉ FOIA.Requests@wales.nhs.uk

[REDACTED]
[REDACTED]
[REDACTED]

Corporate Services
Headquarters
1 Talbot Gateway
Baglan
Port Talbot, SA12 7BR

[REDACTED]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 4th September 2019. Your request sought information relating to breast cancer.

1. Within your health board how many metastatic breast cancer patients are currently [within the past 6 months] being treated, with any therapy, surgery or palliative care.

The number of patients with metastatic breast cancer currently being treated is not held centrally. Information can only be provided for patients at point of presentation but not at any other point in their pathway. To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

2. Within your health board how many breast cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;

- | | |
|--|--------------------|
| • disodium pamidronate (Aredia) | not held centrally |
| • ibandronic acid or ibandronate (Bondronat) | not held centrally |
| • sodium clodronate (Bonefos, Clasteon, Loron) | not held centrally |
| • zoledronic acid or zoledronate (Zometa) | 50 |
| • denosumab (Xgeva) | 39 |



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

3. Within your health board how many breast cancer patients are currently [within the past 6 months] being treated with adjuvant therapy with the following treatments;

- | | |
|--|--------------------|
| • disodium pamidronate (Aredia) | not held centrally |
| • ibandronic acid or ibandronate (Bondronat) | not held centrally |
| • sodium clodronate (Bonefos, Clasteon, Loron) | not held centrally |
| • zoledronic acid or zoledronate (Zometa) | 225 |

4. Within your health board how many metastatic lung cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.

The number of patients with metastatic lung cancer currently being treated is not held centrally. Information can only be provided for patients at point of presentation but not at any other point in their pathway. To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

5. Within your health board how many lung cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;

- | | |
|--|--------------------|
| • disodium pamidronate (Aredia) | not held centrally |
| • ibandronic acid or ibandronate (Bondronat) | not held centrally |
| • sodium clodronate (Bonefos, Clasteon, Loron) | not held centrally |
| • zoledronic acid or zoledronate (Zometa) | <5* |
| • denosumab (Xgeva) | <5* |

* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

6. Within your health board how many metastatic renal cell cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.

The number of patients with metastatic renal cell cancer currently being treated is not held centrally. Information can only be provided for patients at point of presentation but not at any other point in their pathway. To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.



7. Within your health board how many renal cell carcinoma [RCC] patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;

- | | |
|--|--------------------|
| • disodium pamidronate (Aredia) | not held centrally |
| • ibandronic acid or ibandronate (Bondronat) | not held centrally |
| • sodium clodronate (Bonefos, Clasteon, Loron) | not held centrally |
| • zoledronic acid or zoledronate (Zometa) | 6 |
| • denosumab (Xgeva) | Nil |

Please note that where we were have indicated this information is not held centrally, to obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

I hope this information is helpful. If you require anything further please contact us at FOIA.Requests@wales.nhs.uk.

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via FOIA.Requests@wales.nhs.uk.

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



Pam Wenger
Director of Corporate Governance

